doi: 10.3390/nu12082464 55 ZhanXFletcherLDingleSBaracuhyEWangBHuberLAet al
GLP-1RAs vary in their efficacy in reducing HbA1c, magnitude of weight loss, duration of action, dosing frequency, and side effects
Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025
And it's a history with its share of ignominy: In the mid-1990s, a drug that combined fenfluramine and phentermine, known as fen-phen, exploded in popularity after a single, 121-patient study showed it was effective for weight loss
Furthermore, the old Daily Greens formula was a capsule-based supplement